News

Emalex Biosciences Announces Completion of Patient Enrollment in Phase 2b Clinical Trial Evaluating Ecopipam (EBS-101) for Pediatric Patients with Tourette Syndrome

– Paragon Biosciences’ Portfolio Company Focuses on Areas with High Unmet Needs–  Chicago, June 22, 2021 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced today that its Phase 2b clinical … Read more

First Patient Dosed in Emalex Biosciences Phase 2 Clinical Trial for Stuttering

– Speak Freely Study Investigates Ecopipam for Childhood-Onset Fluency Disorder –  Chicago – December 15, 2020 – Emalex Biosciences, Inc. (“Emalex”), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system movement disorders and fluency disorders, announced that the first adult patient has been … Read more